Identification of chalcones as potent and selective PDE5A1 inhibitors

Bioorganic & Medicinal Chemistry Letters
2012.0

Abstract

Chalcones have an affinity for many receptors, enzymes, and transcription factors as flavonoid analogues. Their most studied pharmacological action is that of vasodilatation due to inhibition of phosphodiesterase 5A1 (PDE5A1). To this end, we have established a recursive partitioning model with 3 chemical descriptors for the prediction of compounds that can inhibit PDE5A1. This model was able to predict active compounds with an accuracy of 82.8%. Compound 4 was found to be a potent and selective inhibitor, with a relatively low IC(50) value. The binding mechanism of this compound was also investigated through molecular docking studies.

Knowledge Graph

Similar Paper

Identification of chalcones as potent and selective PDE5A1 inhibitors
Bioorganic & Medicinal Chemistry Letters 2012.0
Chalcones: A Valid Scaffold for Monoamine Oxidases Inhibitors
Journal of Medicinal Chemistry 2009.0
Design, Synthesis, and Structure−Activity Relationship, Molecular Modeling, and NMR Studies of a Series of Phenyl Alkyl Ketones as Highly Potent and Selective Phosphodiesterase-4 Inhibitors
Journal of Medicinal Chemistry 2008.0
Synthesis and QSAR analysis of chalcone derivatives as nitric oxide inhibitory agent
Medicinal Chemistry Research 2012.0
Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5
Bioorganic & Medicinal Chemistry Letters 2019.0
8-(3-Chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors
Bioorganic & Medicinal Chemistry Letters 2015.0
4-(3-Chloro-4-methoxybenzyl)aminophthalazines:  Synthesis and Inhibitory Activity toward Phosphodiesterase 5
Journal of Medicinal Chemistry 2000.0
In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil
Bioorganic & Medicinal Chemistry 2008.0
Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity
Bioorganic & Medicinal Chemistry Letters 2014.0
Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structure–activity relationship
Med. Chem. Commun. 2010.0